AI-generated summary
In this single-blind randomized trial of 70 patients with COVID-19-related dysgeusia, the authors compared active local and systemic red-light photobiomodulation with simulated treatment, with all patients also receiving weekly olfactory therapy. Dysgeusia improved in both groups, and scores were higher in the active group at weeks 7 and 8, which the authors report as an effect. The authors describe the treatment as effective, though the modest difference and single-blind design warrant caution.
- Participants
- 70
- Who or what was studied
- Patients with COVID-19-related dysgeusia (long COVID)
- Limits stated in the abstract
- The abstract reports a single-blind design with a modest between-group difference (p = 0.048) and does not state the wavelength used or the certainty of the evidence.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Total energy
- 3 J, 60 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Long COVID, Randomized controlled trial, Laser, Trial registration, Inflammation, Wavelength, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.